ISPOR Barcelona 2018 Posters

Our 95 poster contributions at ISPOR demonstrate how we are putting science behind new and flexible study designs to address key research questions and specific therapy area challenges, enabling better healthcare decisions globally.

Check back on this page throughout the ISPOR Barcelona 2018 event as we'll be adding new posters after they've been presented.


Monday, November 12
  • DIFFERENTIAL PRICING FRAMEWORK TO EXPEDITE AND EXPAND ACCESS TO INNOVATIVE MEDICINE TO ALL PATIENTS  IN EUROPE
  • REVIEW AND RECOMMENDATIONS OF ENDPOINTS FOR REAL-WORLD STUDIES IN ONCOLOGY
  • EVIDENCE-BASED VALUE OF PD-1/PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICE
  • ONLINE METHODS TO ASSESS THE ELECTRONIC ADAPTATION OF THE TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION
  • PATIENT SATISFACTION WITH TREATMENT: CONCEPTUAL MODELS AND MEASURES
  • IDENTIFYING THE CONFOUNDERS THAT EXPLAIN THE DIFFERENCE IN READOUTS BETWEEN NON- INTERVENTIONAL STUDIES (NIS) AND RANDOMIZED CONTROLLED TRIALS (RCTS): THE CASE OF TREATMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
  • IDENTIFICATION OF THE TREATMENT ATTRIBUTES TO BE CONSIDERED IN SHARED DECISION MAKING FOR ANKYLOSING SPONDYLITIS PATIENTS: A SYSTEMATIC LITERATURE REVIEW
  • THE ACCESS (TIMING AND AVAILABILITY) OF ORPHAN MEDICINE USE AND ITS DETERMINANTS AMONG OECD COUNTRIES FROM 2006 THROUGH 2016
  • REAL WORLD TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PULMONARY ARTERIAL HYPERTENSION IN BRAZIL: A PUBLIC HEALTHCARE DATABASE STUDY
  • SYMPTOM AND IMPACT DISTURBANCE: FINDINGS FROM A QUALITATIVE ASSESSMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
  • CHARACTERIZATION OF PREVENTIVE TREATMENT IN EPISODIC AND CHRONIC MIGRAINE PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY
  • TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES

Tuesday, November 13
  • LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF STATIN INTOLERANT PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY
  • LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY
  • HEART FAILURE SIGNS AND SYMPTOMS AND REFERRALS TO HOSPITAL ARE REDUCED FOLLOWING SACUBITRIL/VALSARTAN TREATMENT IN THE PRIMARY CARE AND CARDIOLOGIST SETTING IN GERMANY
  • COST COMPARISON: STRATEGIES OF PATIENTS MANAGEMENT IN ORAL ANTICOAGULANT THERAPY
  • PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): WHAT HAPPENS BEFORE THE DIAGNOSIS? A REAL-WORLD, RETROSPECTIVE, PRIMARY CARE DATABASE ANALYSIS
  • TREATMENT COSTS AND PROGRESSION-FREE SURVIVAL OF DVD AND KRD REGIMENS SEQUENCES IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
  • COST-OFFSETS ASSOCIATED WITH THE NEW TRIPLETS AVAILABLE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RESOURCE CONSUMPTION DERIVED FROM ITALIAN REAL PRACTICE
  • CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC HORMONE RECEPTOR POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE (HER2-) BREAST CANCER IN CLINICAL PRACTICE: RETROSPECTIVE ANALYSIS FROM LEEDS CANCER CENTRE

Wednesday, November 14
  • TIME TO REIMBURSEMENT OF ONCOLOGY DRUGS IN BRAZIL: AN EXPLORATORY ANALYSIS FROM 2012 TO 2018
  • DO HEALTH TECHNOLOGY APPRAISALS HAVE AN IMPACT?: A COMPARISON OF CENTRALIZED AND REGIONAL APPROACHES
  • CHALLENGES AND OPPORTUNITIES IN CLINICAL NUTRITION IN ONCOLOGY: AVAILABLE EVIDENCE, REAL WORLD PRACTICES, AND THE WAY FORWARD
Contact Us
Contact Us

Email Us

Interested in learning more about how IQVIA can create solutions to help you drive healthcare forward?

Call Us

We're available during standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.